Drug Profile
Research programme: skin disorder therapies - York Pharma
Alternative Names: Skin protease inhibitors - York Pharma; VAMP inhibitors - York Pharma; Vitamin A metabolic pathway inhibitors - York Pharma; YP 003 programme - York Pharma; YP 004Latest Information Update: 04 Apr 2011
Price :
$50
*
At a glance
- Originator York Pharma
- Class
- Mechanism of Action Peptide hydrolase inhibitors; Retinoic acid metabolism modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atopic dermatitis; Malignant melanoma; Psoriasis
Most Recent Events
- 24 Feb 2006 Preclinical trials in Malignant melanoma in United Kingdom (unspecified route)
- 13 Sep 2005 Preclinical trials in Atopic dermatitis in United Kingdom (Topical)
- 13 Sep 2005 Preclinical trials in Psoriasis in United Kingdom (Topical)